Mimedx Group, Inc.: Form 10-Q for the period ended Jun 30, 2023
Filed with the SEC on Aug 1, 2023 and accepted by EDGAR at Aug 1, 2023, 20:04 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2023-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2023-04-01 to 2023-06-30 | $81.3m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 6 months2023-01-01 to 2023-06-30 | $152.9m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months2023-04-01 to 2023-06-30 | $13.6m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 6 months2023-01-01 to 2023-06-30 | $26.0m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months2023-04-01 to 2023-06-30 | $67.7m | us-gaap:GrossProfit |
| Gross profit | 6 months2023-01-01 to 2023-06-30 | $126.9m | us-gaap:GrossProfit |
| Research and development | 3 months2023-04-01 to 2023-06-30 | $8.5m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2023-01-01 to 2023-06-30 | $15.0m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2023-04-01 to 2023-06-30 | $51.9m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months2023-01-01 to 2023-06-30 | $104.2m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2023-04-01 to 2023-06-30 | $2.8m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2023-01-01 to 2023-06-30 | −$590.0k | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2023-04-01 to 2023-06-30 | −$74.0k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months2023-01-01 to 2023-06-30 | −$23.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2023-04-01 to 2023-06-30 | $1.2m | us-gaap:NetIncomeLoss |
| Net income | 6 months2023-01-01 to 2023-06-30 | −$3.8m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2023-04-01 to 2023-06-30 | $0.00 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2023-01-01 to 2023-06-30 | −$0.06 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2023-04-01 to 2023-06-30 | $0.00 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2023-01-01 to 2023-06-30 | −$0.06 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2023-04-01 to 2023-06-30 | 115,866,371 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2023-01-01 to 2023-06-30 | 115,136,646 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months2023-01-01 to 2023-06-30 | $3.7m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2023-01-01 to 2023-06-30 | $932.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2023-06-30 | $68.7m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2023-06-30 | $141.2m | us-gaap:AssetsCurrent |
| Total assets | At period end2023-06-30 | $176.4m | us-gaap:Assets |
| Current liabilities | At period end2023-06-30 | $44.5m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2023-06-30 | $96.5m | us-gaap:Liabilities |
| Long-term debt | At period end2023-06-30 | $48.8m | us-gaap:LongTermDebtNoncurrent |
| Shareholders' equity | At period end2023-06-30 | −$12.7m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001376339-23-000063. Last ingested by Listed: Oct 24, 2026, 15:09 ET. Listed shows no prices and gives no investment advice.